Tregalizumab
Tregalizumab is a monoclonal antibody designed for the treatment of autoimmune diseases. It is a humanized antibody that binds to the CD4 receptor on certain T cells. It was developed by Biotest.
Mechanism of action[edit | edit source]
Tregalizumab binds to a specific site on the CD4 receptor that is only exposed on regulatory T cells (Tregs). This binding enhances the suppressive function of Tregs, which in turn reduces the activity of effector T cells, the cells that cause damage in autoimmune diseases.
Clinical trials[edit | edit source]
Tregalizumab has been tested in several clinical trials. In a phase II trial for rheumatoid arthritis, it showed a trend towards efficacy but did not meet its primary endpoint. Further development for this indication was therefore halted. However, it is still being investigated for other autoimmune diseases.
References[edit | edit source]
See also[edit | edit source]
Tregalizumab Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.Contributors: Prab R. Tumpati, MD